ASH 2022 | Highlights in multiple myeloma: improving access to CAR-T therapy, novel targets & future outlooks

The multiple myeloma treatment landscape has transformed over the years with the introduction and approval of CAR-T cell therapy, and these agents have provided valuable options for patients with relapsed/refractory (R/R) disease. In this discussion, experts Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, and Krina Patel, MD, Msc, The University of Texas MD Anderson Cancer Center, Houston, TX, share key updates in multiple myeloma (MM) presented at the 2022 ASH Annual Meeting, drawing focus on the role of CAR-T therapy and challenges with access to these agents. First, Dr Lin and Dr Patel highlight real-world experiences with access to CAR-T therapy, the importance of optimizing the sequencing of BCMA-targeting agents, and racial disparities in the outcomes of patients with myeloma. Following this, Dr Lin and Dr Patel discuss challenges in treating patients with high-risk and R/R disease, ongoing clinical trials in this space, and the value of moving CAR-T into earlier lines of therapy. To conclude, the experts comment on the promise of bispecific antibodies, novel targets being explored, and the excitement around allogeneic platforms. This discussion took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.